N@N

CDEX Inc.: New Global Study on Medication Errors Supports the ValiMed(TM) International Expansion Initiatives

^{Published on 2009-03-16 07:17:30, Last Modified on 2009-11-03 19:19:10 - Market Wire}
 

TUCSON, AZ--(Marketwire - March 16, 2009) - CDEX Inc. (OTCBB: [ CEXI ]). A March 12, 2009 report published in the British Medical Journal (BMJ 2009;338:b814), concluded that based on evaluations of more than 1300 patients in intensive care units over a 24-hour period across 27 countries, including the US, the administration of intravenous medication is a very serious patient safety problem. The study revealed that almost one in five (19%) patients experienced one medication error and 14% experienced more than one error. The study also found that of the 441 patients affected, twelve suffered permanent harm including five deaths. Over 20% of the errors related to wrong drug or wrong dose, which accounted for a disproportionally higher percentage of the incidents of severe harm to patients and involved many types of drugs, including insulin for diabetics, sedatives and blood-clotting drugs.

"This study confirms findings in previous reports regarding medication errors in hospitals, which have consistently supported the need for the ValiMed System -- to provide assurance of the right drug at the right dose every time," said Pascal Pouligny, GM of CDEX's Medication Safety Division. "In 2008 we made the decision to build a global distribution network for the ValiMed product line and this new study confirms the basis for our decision -- medication errors represent a global problem that is seriously harming patients every day and ValiMed provides a solution now. In a previously published study by C.S. Mott Children's Hospital in the University of Michigan Health System, ValiMed identified five serious medication errors and 'consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.' (See Am J Health-Syst Pharm -- Vol 65, pp 49-54, Jan 1, 2008.) Studies such as these published in major Medical Journals will definitely help our ongoing efforts to promote ValiMed as the new standard for safe compounding and delivery of high-risk medications," added Pouligny.

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts or illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, visit [ www.cdexinc.com ].

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.